Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.
Dan George, MD, Duke Cancer Center
Advertisement
Articles by Dan George, MD, Duke Cancer Center
Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.
Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.
Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.
Advertisement
Latest Updated Articles
Advanced Prostate Cancer: New Findings From ASCO GU 2021March 8th 2021
Risk Factors in Advanced Prostate CancerMarch 9th 2021
Advanced Prostate Cancer: Remaining ChallengesMarch 9th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5